Evidence map›Paper›PMID 23778884›Full record

ReviewHuman vaccines & immunotherapeutics2013

Particle based vaccine formulations for transcutaneous immunization.

Ankit Mittal, Anne S Raber, Claus-Michael Lehr, Steffi Hansen

Abstract readReview
In one paragraph

Review in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Enhanced transdermal delivery of meloxicam by nanocrystals: Preparation,Asian journal of pharmaceutical sciences · 2018
    Article
  5. Article
  6. Review
  7. Applications of nanomaterials as vaccine adjuvants.Human vaccines & immunotherapeutics · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ankit MittalBiopharmaceutics and Pharmaceutical Technology; Saarland University; Saarbruecken, Germany.
Anne S Raber
Claus-Michael Lehr
Steffi Hansen

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccine formulations on the basis of nano- (NP) or microparticles (MP) can solve issues with stabilization, controlled release, and poor immunogenicity of antigens. Likewise transcutaneous immunization (TCI) promises superior immunogenicity as well as the advantages of needle-free application compared with conventional intramuscular injections. Thus the combination of both strategies seems to be a very valuable approach. However, until now TCI using particle based vaccine formulations has made no impact on medical practice. One of the main difficulties is that NPs and MPs cannot penetrate the skin to an extent that would allow the application of the required dose of antigen. This is due to the formidable stratum corneum (SC) barrier, the limited amount of antigen in the formulation and often an insufficient immunogenicity. A multitude of strategies are currently under investigation to overcome these issues. We highlight selected methods presenting a spectrum of solutions ranging from transfollicular delivery, to devices disrupting the SC barrier and the combination of particle based vaccines with adjuvants discussing their advantages and shortcomings. Some of these are currently at an experimental state while others are already in clinical testing. All methods have been shown to be capable of transcutaneous antigen delivery.

Indexed as

Administration, CutaneousClinical Trials as TopicDrug Evaluation, PreclinicalHumansImmunizationNanoparticlesVaccinesVaccinesadjuvantdeliverydermabrasionjet injectormicroneedlemicroparticlesnanoparticlestransfollicular

Identifiers

PMID23778884
PMCPMC3906361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.